Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 7/20 | 0.33 |
| ▸ | CPA1 | P15085 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL34640 | 0.87 | ALDH1A1 (0.39) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 | |
| Trifluoromethanesulfonic Acid SCHEMBL34579 | 0.83 | ALDH1A1 (0.40) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 | |
| SCHEMBL34778 | 0.82 | HIF1A (0.42) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 | |
| Sulfuric Acid SCHEMBL30331189 | 0.81 | HIF1A (0.47) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 | |
| Trifluoroacetic Acid SCHEMBL23883190 | 0.79 | ALDH1A1 (0.42) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 | |
| SCHEMBL35255 | 0.78 | HIF1A (0.44) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 | |
| Bicarbonate SCHEMBL7632183 | 0.77 | ALDH1A1 (0.61) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 | |
| SCHEMBL34197 | 0.76 | TRAP1 (0.39) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 | |
| Oxalic Acid SCHEMBL7635783 | 0.75 | ALDH1A1 (0.59) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 | |
| Bicarbonate SCHEMBL7629482 | 0.75 | ALDH1A1 (0.59) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2473277-B1 | PALLADIUM CATALYST SYSTEM COMPRISING ZWITTERION OR ACID-FUNCTIONALIZED IONIC LIQUID | UNIV DENMARK TECH DTU (DK) | 2019-07-03 | — | — | EP | disclosed |
| US-20170341067-A1 | Palladium Catalyst System Comprising Zwitterion And/Or Acid-Functionalyzed Ionic Liquid | UNIV DENMARK TECH DTU (DK) | 2017-11-30 | — | — | US | disclosed |
| EP-2473277-A1 | PALLADIUM CATALYST SYSTEM COMPRISING ZWITTERION AND/OR ACID-FUNCTIONALIZED IONIC LIQUID | Technical University of Denmark (DK) | 2012-07-11 | — | — | EP | disclosed |
| US-20110065950-A1 | PALLADIUM CATALYST SYSTEM COMPRISING ZWITTERION AND/OR ACID-FUNCTIONALYZED IONIC LIQUID | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2011-03-17 | — | — | US | disclosed |
| WO-2011026860-A1 | PALLADIUM CATALYST SYSTEM COMPRISING ZWITTERION AND/OR ACID-FUNCTIONALIZED IONIC LIQUID | TECHNICAL UNIVERISTY OF DENMARK (DK) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065950-A1 | PALLADIUM CATALYST SYSTEM COMPRISING ZWITTERION AND/OR ACID-FUNCTIONALYZED IONIC LIQUID | PDCD2L, PCCA, PDK2 | ALDH1A1 717/4885CYP1A2 2408/4885CYP2D6 2014/4885 |
| US-20170341067-A1 | Palladium Catalyst System Comprising Zwitterion And/Or Acid-Functionalyzed Ionic Liquid | PDCD2L, PCCA, PDK2 | ALDH1A1 717/4885CYP1A2 2408/4885CYP2D6 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.